Skip to main content

Advertisement

SpringerLink
Log in

Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Introduction

Endothelial-cell-specific molecule-1 or endocan is a proteoglycan with tumorigenic activity through both its glycan and protein cores. Endocan mRNA is identified as one of the most significant molecular signatures defining a poor prognosis in lung, breast, kidney, and hepatocellular cancer.

Objective

To assess the clinical value of endocan expression in ovarian cancer tissues in association with other prognostic factors and its impact on overall survival.

Setting

Oncology unit of Zagazig University Hospitals, Egypt.

Study design

Prospective observational cohort.

Patients and methods

One hundred primary ovarian cancer patients were recruited as study group, another 100 patients undergoing hysterectomy and oophorectomy due to uterine fibroid were the control group. Angiogenesis was determined by immunohistochemical staining, using anti-endocan, and anti vascular endothelial growth factor (VEGF) monoclonal antibodies.

Results

Endocan was expressed in endothelium of ovarian cancer tissue specimens in all patients with no expression in endothelium of normal ovarian tissue in the control group. VEGF was also expressed in endothelium of all specimens of ovarian cancer tissue, compared with 70 % expression in normal ovarian tissue specimens in the control group. A significant association was found between endocan-microvessel density (MVD) and tumor histology, tumor size, staging, and grading. No significant association was found between VEGF expression and any of the clinicopathological variables. Overall survival of patients was inversely associated with endocan-MVD (P < 0.01). Multivariate analysis showed that endocan-MVD was an independent prognostic marker for overall survival of epithelial ovarian cancer (P < 0.01).

Conclusion

Endocan could be a reliable marker to predict the survival in epithelial ovarian cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT et al (2005) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192

    Google Scholar 

  2. Collinson FJ, Seligmann J, Perren TJ (2012) Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents. Curr Oncol Rep (Epub ahead of print)

  3. Eskander RN, Tewari KS (2012) Emerging treatment options for management of malignant ascites in patients with ovarian cancer. Int J Womens Health 4:395–404

    PubMed  CAS  Google Scholar 

  4. Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, Franchi D (2012) Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series. Ann Oncol (Epub ahead of print)

  5. Goodheart MJ, Ritchie JM, Rose SL, Fruehauf JP, De Young BR, Buller RE (2005) The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res 11:3733–3742

    Article  PubMed  CAS  Google Scholar 

  6. Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA (2009) Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group Study. Gynecol Oncol 112:469–474

    Article  PubMed  CAS  Google Scholar 

  7. Wang Y, Mao H, Hao Q, Wang Y, Yang Y, Shen L, Huang S, Liu P (2012) Association of expression of XIAP-associated factor 1 (XAF1) with clinicopathologic factors, overall survival, microvessel density and cisplatin-resistance in ovarian cancer. Regul Pept 178(1–3):36–42

    Article  PubMed  CAS  Google Scholar 

  8. Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011) Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol 32(3):589–596

    Article  PubMed  CAS  Google Scholar 

  9. Ferrero A, Dompè D, Ravarino N, Ramella A, Fuso L, Maggiorotto F, Tripodi E, Zola P (2011) Angiogenesis and molecular markers in advanced epithelial ovarian cancer: a retrospective study. Gynecol Oncol 123(2):301–307

    Article  PubMed  CAS  Google Scholar 

  10. Fiedler U, Christian S, Koidl S, Kerjaschki D, Emmett MS et al (2006) The sialomucin CD34 is a marker of lymphatic endothelial cells in human tumors. Am J Pathol 168:1045–1053

    Article  PubMed  CAS  Google Scholar 

  11. Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447

    Article  PubMed  CAS  Google Scholar 

  12. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochem Biophys Acta 1765:25–37

    PubMed  CAS  Google Scholar 

  13. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536. doi:10.1038/415530a

    Article  Google Scholar 

  14. Chen LY, Liu X, Wang SL, Qin CY (2010) Over-expression of the endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J Int Med Res 38(2):498–510

    Article  PubMed  CAS  Google Scholar 

  15. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 12(15):4575–4582

    Article  PubMed  CAS  Google Scholar 

  16. Poon RT, Ng IO, Lau C et al (2002) Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol 20:1775–1785

    Article  PubMed  Google Scholar 

  17. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY (2008) Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 14(28):4562–4568

    Article  PubMed  CAS  Google Scholar 

  18. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prévot V (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22(6):757–764

    Article  PubMed  CAS  Google Scholar 

  19. Weidner N (1995) Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36:169–180

    Article  PubMed  CAS  Google Scholar 

  20. McDonald DM, Foss AJE (2000) Endothelial cells of tumor vessels: abnormal but not absent. Cancer Metastasis Rev 19:109–120

    Article  PubMed  CAS  Google Scholar 

  21. Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72:136–145

    Article  PubMed  CAS  Google Scholar 

  22. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A et al (2007) Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

We have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Manal M. El Behery, Mahmoud A. Seksaka, Moustafa A. Ibrahiem & Hend S. Saleh

  2. Department of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt

    Yehya El Alfy

Authors
  1. Manal M. El Behery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mahmoud A. Seksaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Moustafa A. Ibrahiem
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hend S. Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yehya El Alfy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manal M. El Behery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El Behery, M.M., Seksaka, M.A., Ibrahiem, M.A. et al. Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet 288, 1371–1376 (2013). https://doi.org/10.1007/s00404-013-2863-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-2863-3

Keywords

Search

Navigation